TY - JOUR T1 - ALBI Grade Is a Predictive Factor of Lenvatinib Treatment Discontinuation due to Adverse Events in Hepatocellular Carcinoma JF - Anticancer Research JO - Anticancer Res SP - 1317 LP - 1323 DO - 10.21873/anticanres.16279 VL - 43 IS - 3 AU - DAICHI ENOMOTO AU - KAZUHIRO YAMAMOTO AU - YUKI MATSUMOTO AU - ASAMI MORIOKA AU - TOMOHIRO OMURA AU - SHOHEI KOMATSU AU - YOSHIHIKO YANO AU - TAKUMI FUKUMOTO AU - IKUKO YANO Y1 - 2023/03/01 UR - http://ar.iiarjournals.org/content/43/3/1317.abstract N2 - Background/Aim: Lenvatinib is a multiple-tyrosine kinase inhibitor used to treat hepatocellular carcinoma (HCC), and its systematic concentration varies according to liver function. The albumin-bilirubin (ALBI) grade is a novel indicator for predicting liver function in patients with hepatic disease. This study aimed to investigate the relationship between ALBI grade and HCC patients’ lenvatinib treatment duration. Patients and Methods: This is a retrospective cohort study of patients with HCC and Child-Pugh A treated with lenvatinib between April 2018 and December 2019. The baseline liver function was determined using the ALBI grade. The primary outcome was discontinuation owing to adverse events. The risk factors for discontinuation owing to adverse effects were analyzed using logistic regression. Results: This investigation included 48 HCC patients. Patients with ALBI grade 2 had a significantly shorter time of discontinuation due to adverse events than those with grade 1 (p=0.036). However, the time of treatment failure did not differ between the groups. Multiple logistic regression analysis showed that ALBI grade 2 and non-use of antihypertensive drugs were independent factors for discontinuation due to adverse events [odds ratio (OR)=14.1, 95% confidence interval (CI)=1.46-135, p=0.022 and OR=5.48, 95% CI=1.13-23.9, p=0.024, respectively]. Conclusion: The ALBI grades may be useful in predicting adverse events caused by lenvatinib in patients with HCC and Child–Pugh A. ER -